Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway

Gene Therapy

Volumn 4, Issue 6, 1997, Pages 611-617

  Scaria, A ^a   St George, J A ^a   Gregory, R J ^a   Noelle, R J ^b   Wadsworth, S C ^a   Smith, A E ^a   Kaplan, J M ^a  

^a GENZYME CORPORATION   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Adenovirus vectors; Anti CD40 ligand; Immune response; Repeat administration

Indexed keywords

CD40 ANTIGEN; GLYCOPROTEIN GP 39; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ADENOVIRUS; AIRWAY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; GENE TRANSFER; HUMORAL IMMUNITY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENE; VIRUS NEUTRALIZATION;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 0030746543     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300431     Document Type: Article

References (40)

1. Stratford-Perricaudet L et al Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1990; 1: 241-256.
2. Rosenfeld MA et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-155.
3. Zabner J et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelium of patients with cystic fibrosis. Cell 1993; 75: 207-216.
4. Crystal RG et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42-51.
5. Zabner J et al. Safety and efficacy of repetitive adenovirusmediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat Genet 1994; 6: 75-83.
6. Yang Y, Li Q, Ertl HCJ, Wilson JM Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
7. Kaplan JM et al. Humoral and cellular immune responses of non-human primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Therapy 1996; 3: 117-127.
8. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus. Nature Med 1996; 2: 545-550.
9. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
10. Yang Y et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet 1994; 7: 362-369.
11. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-6200.
12. Smith TAG et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Gene Therapy 1993; 5: 397-402.
13. Yei S et al. Adenovirus mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Therapy 1994; 1: 192-200.
14. Van Ginkel FW et al. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA anti-bodies to adenovirus and β-galactosidase. Hum Gene Ther 1995; 6: 895-903.
15. Mastrangeli A et al. 'Sero-swith' adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defences against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1996; 7: 79-87.
16. Dai Y et al. Cellular and humoral responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
17. Kay M et al. Long-term hepatic adenovirus-mediated expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191-197.
18. Lenschow DJ et al. CD28/B7 system of T cell costimulation. Ann Rev Immunol 1996; 14: 233-258.
19. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med 1995; 1: 890-893.
20. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76: 241-251.
21. Trinchieri G. Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008-4027.
22. Bliss J et al. IL-12 as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J Immunol 1996; 156: 887-894
23. Yang Y, Xiang Z, Ertl HCJ, Wilson JM. Upregulation of class I major histocompatibility complex antigens by interferon γ is necessary for T-cell-mediated elimination of recombinant adenovinis-infected hepatocytes in vivo Proc Natl Acad Sci USA 1995; 92: 7257-7261.
24. Noelle RJ et al. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 1992, 89, 6550-6554.
25. Foy TM et al. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med 1993; 178: 1567-1575.
26. Kawabe T et al. The immune responses in CD40-deficient mice: impaired immunoglobin class switching and germinal center formation. Immunity 1994; 1: 167-178.
27. Xu J et al. Mice deficient for CD40 ligand. Immunity 1994; 1: 423-431.
28. Foy TM et al. Immune regulation by CD40 and its ligand gp39. Ann Rev Immunol 1996; 14: 591-617.
29. Stuber E, Strober W, Neurath M. Blocking of CD40-CD40L interaction in vivo specifically prevents priming of T helper 1 cells through the inhibition of IL-12 secretion. J Exp Med 1996; 183: 693-698.
30. Stout RD et al. Impaired T cell-mediated macrophage activation in CD40L-deficient mice. J Immunol 1996; 156: 8-11.
31. Foy TM et al. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med 1994; 180: 157-163.
32. Han S et al. Cellular interactions in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J Immunol 1995; 155: 556-567.
33. Durie FH et al. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993; 261: 1328-1330.
34. Durie FH et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest 1994; 94: 1333-1338.
35. Parker DC et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995; 92: 9560-9564.
36. Buhlmann JE et al. In the absence of a CD40 signal, B cells are tolerogenic. Immunity 1995; 2: 645-653.
37. Grouard G, de Bouteiller O, Banchereau J, Liu Y. Human follicular dendritic cells enhance cytokine-dependent growth and differentiation of CD40-activated B cells. J Immunol 1995; 155: 3345-3352.
38. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995; 378: 617-620.
39. Larsen CP et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-438.
40. Ginsberg HS et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 1991; 88: 1651-1655.